relatlimab (BMS-986016) - BMS
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Effect of Nivolumab with or without Relatlimab After Stereotactic Body Radiotherapy in Patients with Advanced Esophagogastric Cancer (SITC 2026) - Oct 2, 2026 - Abstract #473; Pres time: Nov 6, 2026; 10:00 AM - 07:00 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available 
Clinical • Metastases • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Oncology • Solid Tumor
https://www.sitcancer.org/2026/abstracts/titles-and-publications?SITC%202026%20Abstracts%5BhitsPerPage%5D=100
 
Rachel Keogh; Julie Deutsch; Ali Zaidi; Kellie Smith; Kristen Marrone; Josephine Feliciano; Gavin Pereira; Samira Hosseini-Nami; Chen Hu; K. Ranh Voong; Russell Hales; Ronan Kelly; Valsamo Anagnostou; Vincent Lam
 
Oct 2, 2026
 
Prev Next